Related Experiment Video
Updated: Feb 2, 2026

Author Spotlight: Exploring the Mysteries of Sichuan's Herbal Medicine in Chinese Medicine Research
Published on: March 1, 2024
Is Conversion from Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium Justifiable for Gastrointestinal
Kyle M Gardiner1,2, Susan E Tett3, Christine E Staatz3
1School of Pharmacy, University of Queensland, Brisbane, QLD, 4102, Australia. kyle.gardiner@qut.edu.au.
Background:
Globally, enteric-coated mycophenolate sodium (EC-MPS) is replacing mycophenolate mofetil (MMF) in maintenance immunosuppressant regimens. The predominant reason for conversion is the purported improvement in gastrointestinal (GI) quality of life. This paper considers the level of bias associated with studies comparing EC-MPS and MMF for GI-related improvement and provides insight into whether conversion is supported by evidence.
Methods:
Using a pre-determined protocol, a literature search was conducted. Full-text review, data extraction and risk of bias analysis was conducted by two independent authors using the Cochrane domain-based evaluation of risk of bias. The review was reported according to the preferred reporting items for systematic reviews and meta-analyses.
Results:
Twenty-nine studies were included in risk of bias analysis. Of these, only three were deemed a low risk of bias. Across these three studies, there were no statistically significant differences in the proportion of GI-related adverse events nor was there a significant difference in the GI-related quality of life between EC-MPS- and MMF-treated patients in these data.
Conclusion:
There was a high risk of bias across the 29 studies investigating conversion from MMF to EC-MPS for potential improvement in GI-related quality of life. The consolidated results of the three studies with low risk of bias suggest no evidence to convert patients stabilised on MMF. If a patient experiences GI-related adverse events whilst taking MMF, other methods should be explored before conversion to EC-MPS.
Insights
Enteric-coated mycophenolate sodium (EC-MPS) is replacing mycophenolate mofetil (MMF) for improved gastrointestinal (GI) quality of life. However, a review found high bias in studies, with low-bias studies showing no significant GI benefit from EC-MPS over MMF.
Area of Science:
- Transplantation and immunology
- Pharmacology
- Gastroenterology
Background:
- Enteric-coated mycophenolate sodium (EC-MPS) is increasingly used as a replacement for mycophenolate mofetil (MMF) in immunosuppressive therapy.
- The primary driver for this switch is the claimed enhancement of gastrointestinal (GI) quality of life.
Purpose of the Study:
- To critically evaluate the bias in existing studies comparing EC-MPS and MMF regarding GI outcomes.
- To determine if current evidence supports the conversion from MMF to EC-MPS for GI benefit.
Main Methods:
- A systematic literature search was performed following a pre-defined protocol.
- Two independent reviewers assessed study quality using the Cochrane risk of bias tool.
- Data extraction and analysis adhered to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.
Main Results:
- Twenty-nine studies were analyzed for risk of bias; only three met criteria for low risk.
- In these low-risk studies, no statistically significant differences were observed in GI adverse events or GI-related quality of life between EC-MPS and MMF groups.
- The majority of studies exhibited a high risk of bias.
Conclusions:
- A high risk of bias pervades studies examining the switch from MMF to EC-MPS for improved GI quality of life.
- Evidence from low-bias studies does not support converting patients stable on MMF to EC-MPS.
- Alternative strategies should be considered for managing GI adverse events before contemplating a switch to EC-MPS.
Related Concept Videos
Half-life of a Reaction
Gene Conversion
Gene Conversion
Characteristics of Life
The Angiosperm Life Cycle
Conversion of Units
The first step in the unit conversion is to list the given units and the units required...

